HOME >> BIOLOGY >> NEWS
Mouse mimics chronic leukemia, will aid drug development

COLUMBUS , Ohio -- A study by cancer researchers here reveals that a new strain of mice offers the first real animal model for an incurable form of chronic leukemia and should greatly aid the development of new drugs for the disease.

The mouse, called the TCL-1 transgenic mouse, develops a malignancy that closely mimics chronic lymphocytic leukemia (CLL). The lack of an animal model has greatly hampered the development of new treatments for CLL as well as research into its causes and the changes that drive drug resistance.

"This mouse strain shares many of the molecular and genetic features of human CLL, responds to drugs typically used to treat the disease and develops drug resistance that renders treatment ineffective, as often happens in CLL patients," says principal investigator John C. Byrd, professor of internal medicine.

Byrd is a specialist in CLL at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James).

"The strain should be extremely valuable for the development and testing of both conventional drugs and those aimed at molecular targets for CLL."

The findings are published in the Aug. 15 issue of the journal Blood, which includes a commentary about the significance of the research.

An estimated 10,000 Americans will develop CLL in 2006, and about 4,600 will die of the disease. The malignancy usually strikes people aged 50 or older and causes the proliferation of white blood cells called lymphocytes. Other effects include severe anemia and a high risk of viral, bacterial and fungal infections. Average survival after diagnosis is eight to 12 years. The standard treatment for CLL is the drug fludarabine, but the disease often becomes resistant to the drug.

This TCL-1 mouse strain was originally developed by OSU cancer researcher Carlo M. Croce, professor and chair, department of molecular viro
'"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University
22-Aug-2006


Page: 1 2

Related biology news :

1. Mouse model advances understanding of synovial sarcoma
2. Mouse FH knockout resembles human renal cell cancer
3. Mouse stem cell line advance suggests potential for IVF-incompetent eggs
4. Mouse model underestimates the critical role of Tyk2 in human immune system
5. Mouse DNA to aid biomedical research
6. Mouse strain with gene stutter will help leukemia research
7. Knockout Mouse Project
8. NIH launches Knockout Mouse Project
9. Mouse, frog and bird put Snail and Slug to different uses
10. Mouse study reveals human X-SCID gene therapy poses substantial cancer risk
11. Mouse to man: The story of chromosomes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/31/2018)... ... October 30, 2018 , ... ... of Operations. With more than 20 years of antibody purification and management experience, ... biomanufacturing industry. Heidinger joins Azzur from ImmunoReagents, a company he co-founded and managed ...
(Date:10/31/2018)... ... October 31, 2018 , ... ... FebriDx® test, clearing the way for its immediate launch in the European Union ... simple to use point-of-care test that is expected to contribute towards a diagnostic ...
(Date:10/26/2018)... ... October 26, 2018 , ... ... MD, President of Sapphire Women’s Health Group and prominent women’s health expert, ... from around the world, Dr. Moore will bring to uBiome her expertise on ...
Breaking Biology News(10 mins):
(Date:10/18/2018)... ... October 18, 2018 , ... R3 Stem Cell is now offering a 20% ... workshop. The discount is good through November 7th, 2018, with the course taking place ... training workshop includes an amazing useful array of hands on therapies with real patients. ...
(Date:10/18/2018)... ... ... With rapid technological advances in the fertility field, increasing numbers of women ... a cancer diagnosis requiring chemotherapy or removal of an ovary, most women who freeze ... do not want to get pregnant now but may want to in the future. ...
(Date:10/17/2018)... ... October 17, 2018 , ... Catalent ... for drugs, biologics and consumer health products, today announced that Cornell Stamoran, Ph.D., ... present at the annual Partnership Opportunities in Drug Delivery (PODD) meeting at the ...
(Date:10/16/2018)... SAN FRANCISCO (PRWEB) , ... October 16, 2018 ... ... addition of Dr. Isabel Moreno-Indias, PhD, Senior Researcher at the Biomedical Research ... Research in the Physiopathology Network of Obesity and Nutrition, to its Scientific Advisory ...
Breaking Biology Technology:
Cached News: